|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
BEFREE |
We report on an infant with JMML with somatic KRAS G12A mutation and monosomy 7 who achieved sustained remission following azacitidine monotherapy.
|
31250550 |
2019 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
BEFREE |
In the present study, we report 2 patients with somatic mosaicism for oncogenic NRAS mutations (G12D and G12S) associated with the development of JMML.
|
22753870 |
2012 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
|
21169357 |
2011 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.
|
19358724 |
2009 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
|
19047918 |
2009 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.
|
17910045 |
2008 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
GeneticVariation
|
UNIPROT |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
|
17704260 |
2007 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
|
15696205 |
2005 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.820 |
CausalMutation
|
CLINVAR |
Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
|
15842656 |
2005 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The inducible somatic KRAS mutation (G12D) was observed in nine (36%) of CRC patients, and in two (13.3%) of adenoma patients.
|
31692030 |
2020 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
Using the LA2 K-Ras G12D-induced model for lung cancer, we show that Kif2b expression reduces the number of chromosome segregation defects but does not change the incidence of lung tumor lesions.
|
31179849 |
2019 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The results of the KRAS mutational analysis have shown that the majority of somatic mutations in the KRAS affect only one codon, mainly codon 12(p.G12D) with low frequency in adenomas (13.3%) versus CRCs (36%).
|
30997628 |
2019 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
|
31309326 |
2019 |
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
Colorectal Carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
In this study, we have investigated the delivery and transfection of wild-type (wt-) p53 and microRNA-125b (miR-125b) expressing plasmid DNA, in SK-LU-1 human lung adenocarcinoma cells as well as in Kras(G12D)/p53(fl/fl) (KP) genetically engineered mouse model of lung cancer.
|
26686386 |
2016 |
|
Carcinoma of lung
|
|
0.800 |
GeneticVariation
|
BEFREE |
To substantiate these results, an allitinib-sensitive lung cancer-derived cell line (H292) was transfected with plasmids carrying the two most common activating KRAS mutations (p.G12D and p.G12S).
|
26920031 |
2016 |